PHIO vs. PIRS, KPRX, ELAB, GHSI, MIRA, AVTX, HUGE, CMMB, AEZS, and RNAZ
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Pieris Pharmaceuticals (PIRS), Kiora Pharmaceuticals (KPRX), Elevai Labs (ELAB), Guardion Health Sciences (GHSI), MIRA Pharmaceuticals (MIRA), Avalo Therapeutics (AVTX), FSD Pharma (HUGE), Chemomab Therapeutics (CMMB), Aeterna Zentaris (AEZS), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical preparations" industry.
Pieris Pharmaceuticals (NASDAQ:PIRS) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
Pieris Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.
Phio Pharmaceuticals has a net margin of 0.00% compared to Phio Pharmaceuticals' net margin of -39.71%. Phio Pharmaceuticals' return on equity of -57.57% beat Pieris Pharmaceuticals' return on equity.
In the previous week, Pieris Pharmaceuticals had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 2 mentions for Pieris Pharmaceuticals and 1 mentions for Phio Pharmaceuticals. Pieris Pharmaceuticals' average media sentiment score of 0.93 beat Phio Pharmaceuticals' score of 0.44 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.
40.1% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 8.9% of Pieris Pharmaceuticals shares are held by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Phio Pharmaceuticals has lower revenue, but higher earnings than Pieris Pharmaceuticals. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Phio Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 447.95%. Given Pieris Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Pieris Pharmaceuticals.
Pieris Pharmaceuticals received 242 more outperform votes than Phio Pharmaceuticals when rated by MarketBeat users. However, 63.16% of users gave Phio Pharmaceuticals an outperform vote while only 61.37% of users gave Pieris Pharmaceuticals an outperform vote.
Summary
Phio Pharmaceuticals beats Pieris Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
